Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice

Clinical and Vaccine Immunology

Volumn 14, Issue 7, 2007, Pages 821-829

  Geurtsen, Jeroen ^a,b   Banus, H Alexander ^c   Gremmer, Eric R ^c   Ferguson, Henke ^c   De La Fonteyne Blankestijn, Liset J J ^c   Vermeulen, Jolanda P ^c   Dormans, Jan A M A ^c   Tommassen, Jan ^a   Van Der Ley, Peter ^b   Mooi, Frits R ^c   Vandebriel, Rob J ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b National Vaccine Institute   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE LPXL2; ALUMINUM HYDROXIDE; BACTERIUM LIPOPOLYSACCHARIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; ACELLULAR VACCINE; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BORDETELLA PERTUSSIS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; EOSINOPHIL COUNT; FEMALE; HISTOPATHOLOGY; HYPERSENSITIVITY REACTION; IMMUNOGLOBULIN BLOOD LEVEL; LOEFFLER PNEUMONIA; LUNG LAVAGE; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CYTOLOGY; DISEASE MODEL; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; LUNG; MICROBIOLOGY; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DISEASE MODELS, ANIMAL; FEMALE; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED BALB C; SPLEEN; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 35748951297     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00074-07     Document Type: Article

References (48)

1. Ausiello, C. M., R. Lande, F. Urbani, A. la Sala, P. Stefanelli, S. Salmaso, P. Mastrantonio, and A. Cassone. 1999. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67:4064-4071.
2. Baldrick, P., D. Richardson, A. W. Wheeler, and S. R. Woroniecki. 2004. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy. J. Appl. Toxicol. 24:261-268.
3. Baldridge, J. R., Y. Yorgensen, J. R. Ward, and J. T. Ulrich. 2000. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18:2416-2425.
4. Banus, H. A., R. J. Vandebriel, H. de Ruiter, J. A. Dormans, N. J. Nagelkerke, F. R. Mooi, B. Hoebee, H. J. van Kranen, and T. G. Kimman. 2006. Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology. Infect. Immun. 74:2596-2605.
5. Berbers, G. A., A. B. Lafeber, J. Labadie, P. E. Vermeer-de Bondt, D. J. Bolscher, and A. D. Plantinga. 1999. A randomized controlled study with whole-cell or acellular pertussis vaccines in combination with regular DTIPV vaccine and a new poliomyelitis (IPV Vero) component in children 4 years of age in The Netherlands. http://www.rivm.nl/bibliotheek/rapporten/105000001.pdf.
6. Boland, G., J. Beran, M. Lievens, J. Sasadeusz, P. Dentico, H. Nothdurft, J. N. Zuckerman, B. Genton, R. Steffen, L. Loutan, J. Van Hattum, and M. Stoffel. 2004. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23:316-320.
7. Bruss, J. B., and G. R. Siber. 2002. Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model. Infect. Immun. 70:4600-4608.
8. Carbonetti, N. H., G. V. Artamonova, R. M. Mays, and Z. E. Worthington. 2003. Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect. Immun. 71:6358-6366.
9. Cassone, A., C. M. Ausiello, F. Urbani, R. Lande, M. Giuliano, A. La Sala, A. Piscitelli, S. Salmaso, et al. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch. Pediatr. Adolesc. Med. 151:283-289.
10. Cassone, A., P. Mastrantonio, and C. M. Ausiello. 2000. Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients? J. Infect. Dis. 182:1575-1577.
11. Cherry, J. D., J. Gornbein, U. Heininger, and K. Stehr. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906.
12. Dabbagh, K., and D. B. Lewis. 2003. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr. Opin. Infect. Dis. 16:199-204.
13. de Melker, H. E., M. A. Conyn-van Spaendonck, H. C. Rumke, J. K. van Wijngaarden, F. R. Mooi, and J. F. Schellekens. 1997. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 3:175-178.
14. de Melker, H. E., F. G. Versteegh, M. A. Conyn-Van Spaendonck, L. H. Elvers, G. A. Berbers, A. van der Zee, and J. F. Schellekens. 2000. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J. Clin. Microbiol. 38:800-806.
15. Dillon, S., A. Agrawal, T. Van Dyke, G. Landreth, L. McCauley, A. Koh, C. Maliszewski, S. Akira, and B. Pulendran. 2004. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172:4733-4743.
16. Elder, K. D., and E. T. Harvill. 2004. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect. Immun. 72:5919-5924.
17. Evans, J. T., C. W. Cluff, D. A. Johnson, M. J. Lacy, D. H. Persing, and J. R. Baldridge. 2003. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi 529. Expert Rev. Vaccines 2:219-229.
18. Giannini, S. L., E. Hanon, P. Moris, M. Van Mechelen, S. Morel, F. Dessy, M. A. Fourneau, B. Colau, J. Suzich, G. Losonksy, M. T. Martin, G. Dubin, and M. A. Wettendorff. 2006. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only. Vaccine 24:5937-5949.
19. Harvill, E. T., P. A. Cotter, and J. F. Miller. 1999. Pregenomic comparative analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis Tohama I in murine models of respiratory tract infection. Infect. Immun. 67:6109-6118.
20. Higgins, S. C., E. C. Lavelle, C. McCann, B. Keogh, E. McNeela, P. Byrne, B. O'Gorman, A. Jarnicki, P. McGuirk, and K. H. Mills. 2003. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J. Immunol. 171:3119-3127.
21. Higgins, S. C., A. G. Jarnicki, E. C. Lavelle, and K. H. Mills. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177:7980-7989.
22. Kapsenberg, M. L. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3:984-993.
23. King, A. J., G. Berbers, H. F. van Oirschot, P. Hoogerhout, K. Knipping, and F. R. Mooi. 2001. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147:2885-2895.
24. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J. Infect. Dis. 181:2087-2091.
25. Mann, P. B., D. Wolfe, E. Latz, D. Golenbock, A. Preston, and E. T. Harvill. 2005. Comparative Toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect. Immun. 73:8144-8152.
26. Martin, M., S. M. Michalek, and J. Katz. 2003. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. 71:2498-2507.
27. McCormack, P. L., and A. J. Wagstaff. 2006. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs 66:931-938.
28. McVernon, J., N. Andrews, M. P. Slack, and M. E. Ramsay. 2003. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361:1521-1523.
29. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:135-145.
30. Mills, K. H., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
31. Nakagawa, Y., H. Maeda, and T. Murai. 2002. Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test. Clin. Diagn. Lab. Immunol. 9:588-597.
32. Okemoto, K., K. Kawasaki, K. Hanada, M. Miura, and M. Nishijima. 2006. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J. Immunol. 176:1203-1208.
33. Persing, D. H., R. N. Coler, M. J. Lacy, D. A. Johnson, J. R. Baldridge, R. M. Hershberg, and S. G. Reed. 2002. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10:S32-S37.
34. Puggioni, F., S. R. Durham, and J. N. Francis. 2005. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60:678-684.
35. Re, F., and J. L. Strominger. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276:37692-37699.
36. Re, F., and J. L. Strominger. 2004. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J. Immunol. 173:7548-7555.
37. Redhead, K., J. Watkins, A. Barnard, and K. H. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61:3190-3198.
38. Reed, S. G., R. N. Coler, and A. Campos-Neto. 2003. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev. Vaccines 2:239-252.
39. Saito, K., T. Yajima, H. Nishimura, K. Aiba, R. Ishimitsu, T. Matsuguchi, T. Fushimi, Y. Ohshima, Y. Tsukamoto, and Y. Yoshikai. 2003. Soluble branched beta-(1,4)glucans from Acetobacter species show strong activities to induce interleukin-12 in vitro and inhibit T-helper 2 cellular response with immunoglobulin E production in vivo. J. Biol. Chem. 278:38571-38578.
40. Salkowski, C. A., G. R. Detore, and S. N. Vogel. 1997. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 65:3239-3247.
41. Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916.
42. Taranger, J., B. Trollfors, T. Lagergard, V. Sundh, D. A. Bryla, R. Schneerson, and J. B. Robbins. 2000. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J. Infect. Dis. 181:1010-1013.
43. Thalen, M., J. van den IJssel, W. Jiskoot, B. Zomer, P. Roholl, C. de Gooijer, C. Beuvery, and J. Trampen. 1999. Rational medium design for Bordetella pertussis: basic metabolism. J. Biotechnol. 75:147-159.
44. Vandebriel, R. J., E. R. Gremmer, J. P. Vermeulen, S. M. Hellwig, J. A. Dormans, P. J. Roholl, and F. R. Mooi. 2007. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine 25:2346-2360.
45. van den Berg, B. M., S. David, H. Beekhuizen, F. R. Mooi, and R. van Furth. 2000. Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. Vaccine 19:1118-1128.
46. van der Ley, P., L. Steeghs, H. J. Hamstra, J. ten Hove, B. Zomer, and L. van Alphen. 2001. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69:5981-5990.
47. Willems, R. J., J. Kamerbeek, C. A. Geuijen, J. Top, H. Gielen, W. Gaastra, and F. R. Mooi. 1998. The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. Vaccine 16:410-416.
48. Zhang, P., Q. B. Yang, D. F. Balkovetz, J. P. Lewis, J. D. Clements, S. M. Michalek, and J. Katz. 2005. Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis. Vaccine 23:4734-4744.